Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor

18Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Bisphosphonates have high affinity for hydroxyapatite (HA), which is abundantly present in bone. Also, platinum complexes are known that have a wide spectrum of antitumor activities. The conjugate of bisphosphonate and a platinum complex might have HA affinity and antitumor activity, and become a drug for metastatic bone tumor. In this study, the authors synthesized platinum complexes that had dialkyl bisphosphonic acid as a ligand, and evaluated the possibility of the synthesized complexes as a drug for metastatic bone tumor. The synthesized dialkyl bisphosphonate platinum(II) complex was characterized, and its stability in an aqueous solution was also confirmed. The synthesized platinum complex showed higher HA affinity than other platinum complexes such as cisplatin and carboplatin in an experiment of adsorption to HA. In vitro, the platinum complex showed tumor growth inhibitory effect stronger than or equal to cisplatin, which is the most commonly used antitumor agent. Moreover, the platinum complex showed a bone absorption inhibitory effect on the osteoclast. These results suggest potential of dialkyl bisphosphonate platinum(II) complexes as a drug for metastatic bone tumor. © 2011 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Nakatake, H., Ekimoto, H., Aso, M., Ogawa, A., Yamaguchi, A., & Suemune, H. (2011). Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor. Chemical and Pharmaceutical Bulletin, 59(6), 710–713. https://doi.org/10.1248/cpb.59.710

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free